Daniel Li
University of California, Los Angeles(US)UCLA Health(US)Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
CAR-T cell therapy research, Biomedical Ethics and Regulation, Biosimilars and Bioanalytical Methods, Advancements in Semiconductor Devices and Circuit Design, SARS-CoV-2 and COVID-19 Research
Most-Cited Works
- → CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients(2016)2,064 cited
- → Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells(2017)1,320 cited
- → Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy(2017)1,083 cited
- → Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells(2016)994 cited
- → Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia(2018)898 cited
- → Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy(2017)547 cited